Peijia Medical Gains NMPA Green Light for SeQuent® Please CIS Drug-Coated Intracranial Balloon Catheter

Bulletin Express

2 hours ago

Hong Kong-listed Peijia Medical Limited announced that the National Medical Products Administration (NMPA) has approved the registration of the SeQuent® Please CIS Paclitaxel Drug-Coated Intracranial Balloon Dilatation Catheter. The device, originally developed by B. Braun Medical (Suzhou) Co., Ltd., uses paclitaxel to curb neointimal hyperplasia during mechanical dilatation, aiming to lower long-term restenosis risk in intracranial vessels with narrow and tortuous anatomy.

Peijia Medical, through its subsidiary Shanghai Achieva Medical Suzhou Co., Ltd., holds exclusive distribution rights for the product in mainland China. Management expects the newly approved catheter to complement the Group’s existing neurointerventional portfolio and enhance its commercial reach in treating intracranial atherosclerotic stenosis.

The company cautioned that successful market launch is not guaranteed and advised shareholders and potential investors to exercise prudence when dealing in its shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1140598767"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140598767\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140598767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-25 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140598767","market":"hk","top_or_hot":-1,"title":"Peijia Medical Gains NMPA Green Light for SeQuent® Please CIS Drug-Coated Intracranial Balloon Catheter","media":"Bulletin Express","content":"<p>Hong Kong-listed Peijia Medical Limited announced that the National Medical Products Administration (NMPA) has approved the registration of the SeQuent® Please CIS Paclitaxel Drug-Coated Intracranial Balloon Dilatation Catheter. The device, originally developed by B. Braun Medical (Suzhou) Co., Ltd., uses paclitaxel to curb neointimal hyperplasia during mechanical dilatation, aiming to lower long-term restenosis risk in intracranial vessels with narrow and tortuous anatomy.</p>\n<p>Peijia Medical, through its subsidiary Shanghai Achieva Medical Suzhou Co., Ltd., holds exclusive distribution rights for the product in mainland China. Management expects the newly approved catheter to complement the Group’s existing neurointerventional portfolio and enhance its commercial reach in treating intracranial atherosclerotic stenosis.</p>\n<p>The company cautioned that successful market launch is not guaranteed and advised shareholders and potential investors to exercise prudence when dealing in its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Peijia Medical Gains NMPA Green Light for SeQuent® Please CIS Drug-Coated Intracranial Balloon Catheter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPeijia Medical Gains NMPA Green Light for SeQuent® Please CIS Drug-Coated Intracranial Balloon Catheter\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-25 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong-listed Peijia Medical Limited announced that the National Medical Products Administration (NMPA) has approved the registration of the SeQuent® Please CIS Paclitaxel Drug-Coated Intracranial Balloon Dilatation Catheter. The device, originally developed by B. Braun Medical (Suzhou) Co., Ltd., uses paclitaxel to curb neointimal hyperplasia during mechanical dilatation, aiming to lower long-term restenosis risk in intracranial vessels with narrow and tortuous anatomy.</p>\n<p>Peijia Medical, through its subsidiary Shanghai Achieva Medical Suzhou Co., Ltd., holds exclusive distribution rights for the product in mainland China. Management expects the newly approved catheter to complement the Group’s existing neurointerventional portfolio and enhance its commercial reach in treating intracranial atherosclerotic stenosis.</p>\n<p>The company cautioned that successful market launch is not guaranteed and advised shareholders and potential investors to exercise prudence when dealing in its shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09996","symbol_name":"沛嘉医疗-B","start_time":0,"source_url":"","article_id":"1140598767","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140598767","pubTimestamp":1790328183,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong-listed Peijia Medical Limited announced that the National Medical Products Administration (NMPA) has approved the registration of the SeQuent® Please CIS Paclitaxel Drug-Coated Intracranial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09996":"沛嘉医疗-B"},"translate_title":"培佳医疗获得NMPA批准后续上市®请顺式药物涂层颅内球囊导管","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09996":1},"content_text":"Hong Kong-listed Peijia Medical Limited announced that the National Medical Products Administration (NMPA) has approved the registration of the SeQuent® Please CIS Paclitaxel Drug-Coated Intracranial Balloon Dilatation Catheter. The device, originally developed by B. Braun Medical (Suzhou) Co., Ltd., uses paclitaxel to curb neointimal hyperplasia during mechanical dilatation, aiming to lower long-term restenosis risk in intracranial vessels with narrow and tortuous anatomy.\nPeijia Medical, through its subsidiary Shanghai Achieva Medical Suzhou Co., Ltd., holds exclusive distribution rights for the product in mainland China. Management expects the newly approved catheter to complement the Group’s existing neurointerventional portfolio and enhance its commercial reach in treating intracranial atherosclerotic stenosis.\nThe company cautioned that successful market launch is not guaranteed and advised shareholders and potential investors to exercise prudence when dealing in its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}